170 related articles for article (PubMed ID: 16828866)
1. Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors.
Biedermann B; Gil D; Bowen DT; Crocker PR
Leuk Res; 2007 Feb; 31(2):211-20. PubMed ID: 16828866
[TBL] [Abstract][Full Text] [Related]
2. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Nguyen DH; Ball ED; Varki A
Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
[TBL] [Abstract][Full Text] [Related]
3. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
4. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
[TBL] [Abstract][Full Text] [Related]
5. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.
Bakker AB; van den Oudenrijn S; Bakker AQ; Feller N; van Meijer M; Bia JA; Jongeneelen MA; Visser TJ; Bijl N; Geuijen CA; Marissen WE; Radosevic K; Throsby M; Schuurhuis GJ; Ossenkoppele GJ; de Kruif J; Goudsmit J; Kruisbeek AM
Cancer Res; 2004 Nov; 64(22):8443-50. PubMed ID: 15548716
[TBL] [Abstract][Full Text] [Related]
6. Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33.
Vercauteren S; Zapf R; Sutherland H
Cytotherapy; 2007; 9(2):194-204. PubMed ID: 17453971
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis.
Knapp W; Strobl H; Majdic O
Cytometry; 1994 Dec; 18(4):187-98. PubMed ID: 7534675
[TBL] [Abstract][Full Text] [Related]
8. Cloning and molecular characterization of two splice variants of a new putative member of the Siglec-3-like subgroup of Siglecs.
Foussias G; Taylor SM; Yousef GM; Tropak MB; Ordon MH; Diamandis EP
Biochem Biophys Res Commun; 2001 Jun; 284(4):887-99. PubMed ID: 11409877
[TBL] [Abstract][Full Text] [Related]
9. Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage.
Bächli EB; Schaer DJ; Walter RB; Fehr J; Schoedon G
J Leukoc Biol; 2006 Feb; 79(2):312-8. PubMed ID: 16368951
[TBL] [Abstract][Full Text] [Related]
10. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
11. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells.
Yokoi H; Myers A; Matsumoto K; Crocker PR; Saito H; Bochner BS
Allergy; 2006 Jun; 61(6):769-76. PubMed ID: 16677248
[TBL] [Abstract][Full Text] [Related]
12. Negative regulation of leucocyte functions by CD33-related siglecs.
Avril T; Attrill H; Zhang J; Raper A; Crocker PR
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1024-7. PubMed ID: 17073742
[TBL] [Abstract][Full Text] [Related]
13. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing.
Hernández-Caselles T; Martínez-Esparza M; Pérez-Oliva AB; Quintanilla-Cecconi AM; García-Alonso A; Alvarez-López DM; García-Peñarrubia P
J Leukoc Biol; 2006 Jan; 79(1):46-58. PubMed ID: 16380601
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells.
Lock K; Zhang J; Lu J; Lee SH; Crocker PR
Immunobiology; 2004; 209(1-2):199-207. PubMed ID: 15481154
[TBL] [Abstract][Full Text] [Related]
15. Residual normal, highly proliferative progenitors can be isolated from the CD34+/33- fraction of AML with a more differentiated phenotype (CD33+).
Raymakers R; Wittebol S; Pennings A; Linders E; Poddighe P; De Witte T
Leukemia; 1995 Mar; 9(3):450-7. PubMed ID: 7533867
[TBL] [Abstract][Full Text] [Related]
16. Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).
Neudenberger J; Hotfilder M; Rosemann A; Langebrake C; Reinhardt D; Pieters R; Schrauder A; Schrappe M; Röttgers S; Harbott J; Vormoor J
Br J Haematol; 2006 May; 133(3):337-44. PubMed ID: 16643437
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Balaian L; Ball ED
Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
[TBL] [Abstract][Full Text] [Related]
18. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
19. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2004 Oct; 10(20):7043-52. PubMed ID: 15501984
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies.
Balaian L; Ball ED
Leuk Res; 2004 Aug; 28(8):821-9. PubMed ID: 15203280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]